Patents by Inventor Gunars E. Valkirs
Gunars E. Valkirs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110065210Abstract: The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.Type: ApplicationFiled: September 2, 2010Publication date: March 17, 2011Inventors: Jeffrey R. Dahlen, Kenneth F. Buechler, Gunars E. Valkirs
-
Patent number: 7655428Abstract: The present invention relates to methods and compositions for measuring latent protein C in test samples, particularly patient samples. The methods and compositions described are sensitive for latent protein C, relative to activated protein C.Type: GrantFiled: December 21, 2006Date of Patent: February 2, 2010Assignee: Biosite, Inc.Inventors: Gunars E. Valkirs, Joseph A. Buechler, Seok-Won Lee, Uday Kumar Veeramallu
-
Patent number: 7632647Abstract: The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.Type: GrantFiled: April 13, 2001Date of Patent: December 15, 2009Assignee: Biosite IncorporatedInventors: Jeffrey R. Dahlen, Kenneth F. Buechler, Gunars E. Valkirs
-
Patent number: 7608406Abstract: The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.Type: GrantFiled: June 23, 2004Date of Patent: October 27, 2009Assignee: Biosite, Inc.Inventors: Gunars E. Valkirs, Jeffrey R. Dahlen, Howard J. Kirchick, Kenneth F. Buechler
-
Patent number: 7427490Abstract: The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.Type: GrantFiled: August 20, 2002Date of Patent: September 23, 2008Assignee: Biosite IncorporatedInventors: Gunars E. Valkirs, Jeffrey R. Dahlen, Howard J. Kirchick, Kenneth F. Buechler
-
Patent number: 7052858Abstract: This invention provides a novel Cryptosporidium parvum protein disulfide isomerase polypeptide, and nucleic acids that encode this polypeptide. The invention also provides methods, reagents, and kits that are useful for diagnosing infection by Cryptosporidium parvum. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the protein disulfide isomerase polypeptide of C. parvum.Type: GrantFiled: June 7, 2001Date of Patent: May 30, 2006Assignee: BIOSITE IncorporatedInventors: Jeff Gray, Gunars E. Valkirs, Joe Buechler
-
Patent number: 6908739Abstract: This invention provides methods, reagents, and kits that are useful for diagnosing infection by Giardia lamblia. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the ?-1-giardin antigen of G. lamblia.Type: GrantFiled: May 23, 2002Date of Patent: June 21, 2005Assignee: Biosite IncorporatedInventors: Joe Buechler, Shanthi Govindaraj, Jeff Gray, Gunars E. Valkirs
-
Patent number: 6828110Abstract: This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthracis.Type: GrantFiled: January 4, 2001Date of Patent: December 7, 2004Assignee: Biosite IncorporatedInventors: Bruce A. Lee, Becky Mar Flores, Gunars E. Valkirs
-
Publication number: 20040219509Abstract: The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.Type: ApplicationFiled: November 14, 2003Publication date: November 4, 2004Applicant: Biosite, Inc.Inventors: Gunars E. Valkirs, Jeffrey R. Dahlen, Howard J. Kirchick, Kenneth F. Buechler
-
Publication number: 20040171064Abstract: The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.Type: ApplicationFiled: March 13, 2003Publication date: September 2, 2004Applicant: Biosite IncorporatedInventors: Jeffrey R. Dahlen, Kenneth F. Buechler, Gunars E. Valkirs
-
Publication number: 20040170967Abstract: This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthracis.Type: ApplicationFiled: January 4, 2001Publication date: September 2, 2004Inventors: Bruce A. Lee, Becky Mar Flores, Gunars E. Valkirs
-
Patent number: 6777190Abstract: Assay for detecting the amount or presence of target ligand in a sample. The assay includes a ligand analogue conjugate having a linkage site and a binding site, a ligand receptor, and a sample. The assay includes the steps of providing at least one crosstalk inhibitor. This inhibitor, under assay conditions, competes with the linkage site of the ligand analogue conjugate for binding to the ligand receptor, and does not compete with the binding site of the ligand analogue conjugate for binding to the ligand receptor. In the invention, the assay is performed for the target ligand in the presence of a sufficient amount of the crosstalk inhibitor to reduce the amount of binding of the linkage site of the ligand analogue conjugate to the ligand receptor. The invention also features a method for identifying crosstalk inhibitors, and the crosstalk inhibitors themselves.Type: GrantFiled: May 11, 1994Date of Patent: August 17, 2004Assignee: Biosite, Inc.Inventors: Kenneth F. Buechler, Richard R. Anderson, Theodore T. Lee, Gunars E. Valkirs
-
Publication number: 20040096454Abstract: This invention provides a novel Cryptosporidium parvum protein disulfide isomerase polypeptide, and nucleic acids that encode this polypeptide. The invention also provides methods, reagents, and kits that are useful for diagnosing infection by Cryptosporidium parvum. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the protein disulfide isomerase polypeptide of C. parvum.Type: ApplicationFiled: June 7, 2001Publication date: May 20, 2004Applicant: Biosite Diagnostics, a Delaware corporationInventors: Jeff Gray, Gunars E. Valkirs, Joe Buechler
-
Publication number: 20030199000Abstract: The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.Type: ApplicationFiled: February 20, 2003Publication date: October 23, 2003Inventors: Gunars E. Valkirs, Jeffery Dahlen, Howard J. Kirchick, Kenneth F. Buechler
-
Publication number: 20030119064Abstract: The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.Type: ApplicationFiled: August 20, 2002Publication date: June 26, 2003Inventors: Gunars E. Valkirs, Jeffrey R. Dahlen, Howard J. Kirchick, Kenneth F. Buechler
-
Publication number: 20030064417Abstract: This invention provides methods, reagents, and kits that are useful for diagnosing infection by Giardia lamblia. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the &agr;-1-giardin antigen of G. lamblia.Type: ApplicationFiled: May 23, 2002Publication date: April 3, 2003Applicant: Biosite Diagnostics, a Delaware corporationInventors: Joe Buechler, Shanthi Govindaraj, Jeff Gray, Gunars E. Valkirs
-
Publication number: 20030022235Abstract: The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.Type: ApplicationFiled: April 13, 2001Publication date: January 30, 2003Inventors: Jeffrey R. Dahlen, Kenneth F. Buechler, Gunars E. Valkirs
-
Patent number: 6503722Abstract: This invention provides methods, compositions, and kits for detecting the presence of toxigenic strains of C. difficile in a biological sample. One embodiment provides methods for C. difficile detection that involve assaying for both C. difficile glutamate dehydrogenase and C. difficile toxin A or toxin B. In another embodiment, the invention provides a highly sensitive assay for C. difficile toxin A that is useful for determining whether a C. difficile strain is toxigenic. This embodiment involves binding of toxin A to a moiety that reversibly binds to a capture moiety present on a magnetic bead. A magnetic field is applied to the sample to concentrate the toxin A, after which the magnetic beads are dissociated and removed from the solution to obtain a highly concentrated preparation of toxin A, thus making possible a very sensitive assay.Type: GrantFiled: July 29, 1999Date of Patent: January 7, 2003Assignee: Biosite DiagnosticsInventor: Gunars E. Valkirs
-
Publication number: 20020127618Abstract: This invention provides a novel Cryptosporidium parvum protein disulfide isomerase polypeptide, and nucleic acids that encode this polypeptide. The inventionalso provides methods, reagents, and kits that are useful for diagnosing infection by Cryptosporidium parvum. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the protein disulfide isomerase polypeptide of C. parvum.Type: ApplicationFiled: September 21, 1998Publication date: September 12, 2002Inventors: JEFF GRAY, GUNARS E. VALKIRS, JOE BUECHLER
-
Patent number: 6348318Abstract: This invention provides methods, compositions and kits for concentrating target ligands, including microorganisms, from samples, including biological samples. The methods involve the use of magnetic particles to concentrate the target analytes. Also provided are methods, compositions and kits for detecting the presence of target ligands in samples.Type: GrantFiled: April 3, 1998Date of Patent: February 19, 2002Assignee: Biosite DiagnosticsInventor: Gunars E. Valkirs